Next Phase Newsletter

A life sciences venture capital firm based in Canada with additional offices in USA manages over $500M AUM and has invested over $450M in more than 100 companies. With their recent fund closed in 2021, the firm typically makes initial investments ranging from $2-$6 million of equity and looks to invest $8-$12 million over the lifetime of the investment. The firm expects to make 4-6 investments over the next 12 months, and prioritizes investment opportunities that are based in USA or Canada.

The firm invests primarily in therapeutics and  medical devices, and consumer health technologies. The firm generally looks for companies phase I and later that have at least some human proof-of-concept with either early human efficacy signs or very strong animal data coupled with human safety data. That said, the firm is open to earlier stage, pre-clinical companies with strong validation. The firm is agnostic in terms of modalities.

The firm invests in companies throughout the United States and Canada. The firm does not look to take an active role on the management team but does look to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global biopharmaceutical company with strong interest to invest and collaborate with clinical & early-stage life science companies has significant experience and expertise in conducting drug development and clinical trials in Asia and China, and they are looking to leverage that to partner up with clinical-stage companies. The firm is open to equity investment, licensing-in, co-development and other partnership models. In terms of equity investments, the firm typically engages in seed to series A investment rounds. The initial check size ranges from $1~ 3M with the possibility for follow-on rounds. The firm is generally interested in companies based in the US and Europe and is open to both leading and co-investing.

The firm is interested in therapeutics and medical devices that provide solutions to unmet needs and have strong market potential in Asia and China. Interested indications include chronic, inflammation and aging-related diseases, oncology, and rare diseases. The firm is also interested in rare diseases as long as there are huge unmet needs. The firm is most interested in therapeutics assets that are in Phase I or Phase II clinical stage but can be flexible if the technology is a good fit.

There are no specific requirements for the company’s management team. The firm might consider a board seat on a case-by-case basis. The firm has a strong presence in China and Asia and is willing to support companies with their expertise and experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment group that was founded by a family office has teams based in USA and Asia. The group is actively seeking new investments in the life sciences. The group invests broadly in therapeutics and digital health. The investment size will vary and typically it ranges from single to double digit millions. The group has no set number of allocations over the next 6-9 months.

In life sciences, the firm’s US team is looking for new investments in digital health and therapeutics. For therapeutics, the group is modality and indication agnostic. The group invests in both preclinical and clinical stage companies. The group is open to lead or syndicate with other investors.

The firm invests in privately-held life science companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm was founded in 2020 and is based in San Francisco, CA. The firm is expecting to close their first fund this year, targeting $100M. The firm is seeking to invest in Seed to Series A companies. The firm expects to make about 80% of their investments in North America, but has a global outlook and has evaluated opportunities from Israel, Japan, Europe, Asia, etc.

Within life sciences, the firm is most interested in digital health technologies, including Digital Therapeutics, AI-powered healthcare solutions, smart devices, and tech-enabled services. The firm will be extremely selective about medical device companies without a digital component. The same applies for traditional therapeutics and diagnostics sectors as well. The firm likes to see early traction (i.e. paying customer engagement), but is open to pre-revenue companies.

The firm is open to working with all kinds of management teams. The firm is capable of leading seed rounds and can act as either lead or co-investor. If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.